Pamela Yates is an undefeated life sciences and product liability trial lawyer who is consistently named one of California’s “Top Women Litigators” and internationally recognized as a “Life Science Star.” Pam is one of a very select group of female product liability litigators in the US who has tried cases in multiple state and federal court venues involving pharmaceuticals and medical devices. Pam has extensive experience in MDL and class action work, and for many years has acted as national coordinating counsel in various mass tort cases. In that role, she has been responsible for all aspects of litigation, including trial, trial preparation and strategy, science and overall Daubert strategy, and settlement, together with management and coordination of regional and local counsel.全部显示
Successfully defending pharmaceutical companies began early in her career when, as a young associate, Pam drafted the summary judgment in Daubert, leading to the US Supreme Court’s decision that ultimately set the standard for challenging the admissibility of expert testimony. Building on her success in Daubert, Pam led Pfizer’s expert and science teams in defending claims relating to hormone therapy (HT) products. In addition to her science related work, Pam served as lead trial defense counsel in several of the HT matters herself and recently secured two defense verdicts in Connecticut and West Virginia. Pam currently heads up Pfizer’s science team in their defense of an antidepressive medicine.
Pam’s stellar work has garnered significant recognition from a number of industry guides. Most recently, Pam was ranked in Best Lawyers in America 2014 for Biotechnology Law and Product Liability Litigation. From 2009-2013, Pam has been recognized as one of California’s top women litigators in Daily Journal’s, supplement feature, “Top Women Litigators.” Pam was also recently recognized as a “Life Science Star” by Euromoney’s 2013 LMG Life Sciences Guide and has been featured in Who’s Who Legal in the areas of Product Liability Defense (2007, 2008, 2009, 2012, and 2013) and in Life Sciences (2010, 2012, and 2013). In January 2006, Kaye Scholer’s product liability lawyers were awarded The American Lawyer Litigation Product Liability Department of the Year. The award specifically references several successes in the Rezulin litigation, which involved Pam. In August 2005, The National Law Journal’s “The Defense Hot List, sizing up Defense Firms With Big Wins” featured Pam’s defense verdict, discussed below, in a multiple plaintiff products case, In Re Rezulin Litigation.
- In May 2012, Pamela, along with Andrew K. Solow (Partner in the New York office), served as co-lead trial counsel for Pfizer units Wyeth, Inc. and Wyeth Pharmaceuticals Inc. in US District Court (Connecticut) and obtained a defense verdict on all counts related to a wrongful death suit involving Wyeth’s hormone therapy (HT) medications Premarin and Prempro. After a three-week trial, the jury dismissed all four of the alleged claims. This decision marks Pamela and Andrew’s second win in less than one year regarding both HT medications. Lynn Gardner Moss, et al. v. Wyeth, Inc., et al.
- In July 2011, Pamela, along with Andrew K. Solow, served as trial counsel for Pfizer units, Wyeth Pharmaceuticals Inc. and Pharmacia & Upjohn Co., and obtained a defense verdict in a case involving claims of injuries from the client’s HT medicines. After a three-week trial, the jury found that the HT prescription medicines did not cause the plaintiff’s breast cancer and that the plaintiff’s claims were time-barred by the applicable statute of limitations. Notably, this was the first defense verdict for Pharmacia & Upjohn in the hormone therapy litigation. Hines v. Wyeth, et al.
- In 2008, Pamela served as trial and coordinating counsel in two HT trials in state and federal court.
- The landmark case of Daubert v. Merrell Dow Pharmaceuticals, Inc., 727 F.Supp. 570 (S.D. Cal. 1989); aff’d 951 F.2d 1128 (1991); 509 U.S. 579 (1993). Daubert sets forth the standard by which judges are to act as gatekeepers in excluding “junk science” from the courtroom.
- Currently acting as coordinating counsel for the science defense in the Zoloft cases for Pfizer Inc.
- Currently acting as national, regional and local counsel for Pfizer Inc. in the hormone therapy litigation. Responsibilities include acting as lead trial counsel, coordinating and implementing the science defense and handling all phases of litigation, involving several hormone therapy products.
- Currently acting as national and local counsel for Endo Pharmaceuticals Inc. in litigation relating to a recall of several oral contraceptive products. Pamela is coordinating all phases of the litigation and has led her team to several successes, including defeating two purported class actions.
- Recently served as national and local counsel for Pfizer Inc. (Warner-Lambert) in the Rezulin (diabetic medication) litigation. Responsibilities covered all aspects of litigation. Pamela obtained defense verdicts against all plaintiffs in the first in the nation consolidated plaintiff trial. All three plaintiffs claimed liver injury from exposure to the medication. All defense verdicts were unanimous. This verdict was featured in The National Law Journal’s “The Defense Hot List: Sizing Up Defense Firms with Big Wins” (August 22, 2005).
- Pamela, along with others on the Kaye Scholer team, won an important Daubert victory in the Rezulin multidistrict litigation (2005 WL 583751 (S.D.N.Y.)). After a two-day hearing, the court ruled that plaintiffs could not rely on their proposed expert testimony that Rezulin caused a “silent” liver injury. Pamela cross-examined the plaintiffs’ lead toxicologist, which was the focus of the court’s Daubert opinion excluding said testimony.
- Previously, Pamela acted as National Coordinating Counsel in the silicone breast implant litigation, representing Baxter Healthcare Corporation and Baxter International Inc. Responsibilities involved handling all phases of litigation, including trials. Pamela obtained defense verdicts in two separate multiple plaintiff trials in Texas. All plaintiffs claimed defective implants due to rupture, negligence, failure to warn, strict liability and fraud. The juries returned defense verdicts on all claims.
- Previously represented Wyeth Inc., defending their diet medications Dexfenfluramine and Fenfluramine in the Phen-Fen litigation. Specifically, Pamela was responsible for deposing and defending expert witnesses, and developing national experts in the areas of cardiology and pulmonology.
- Previously acted as national counsel for Merrell Dow Pharmaceuticals Inc., the manufacturer of Bendectin, an anti-nausea medication for pregnant women. She successfully defended the company against claims of birth defects, ultimately resulting in many courts excluding plaintiff’s expert evidence on the grounds of “junk science,” following her Daubert success.
- She also served as national counsel for pharmaceutical clients in the L-trytophan litigation. Claims involved manufacturing and design defects resulting in Eosinophilia Myalgia Syndrome.
- Defended heart valves and other implantable medical devices on behalf of Baxter Healthcare Corporation.
- Defended multiple clients in toxic tort exposure claims.
- Defended and advised clients in product recalls, including consumer products.
Pro Bono Activities
Pamela is the Los Angeles partner in charge of pro bono activities, ranging from tenant disputes with landlords, asylum cases, death penalty cases, victims of home equity fraud and guardian ad litem cases.
Pamela was a finalist in the philanthropy category for her pro bono leadership at the Los Angeles Business Journal’s 2009 “Women Making A Difference” program and ceremony on May 5, 2009.
Pamela was a recipient of the 2007 Wiley W. Manuel Award for Pro Bono legal services awarded by the State Bar of California’s Board of Governors in recognition of her “voluntary provision of legal services to the poor.”
Publications and Presentations
Served as a faculty member at the International Association of Defense Counsel’s (IADC) 41st Annual Trial Academy, held at Stanford University, Palo Alto, CA, July 27-August 2, 2013.
Presentation at DRI Drug and Medical Device conference, “The Multiple-Plaintiff Pharmaceutical Trial: Keys to a Successful Defense,” New York, NY, May 2013.
Presentation outline: “Taking the Deposition of the Prescriber: The Trial Lawyer’s Perspective” DRI’s Drug and Medical Device Conference, May 10-11, 2012. Speech given by James Herschlein (Partner, NY office).
“Have You Analyzed Potential Daubert Challenges From All Angles?,” IADC Webinar, March 23, 2011.
Invited panelist at the Southwestern Women’s Law Association “Work Life Balance Panel,”
March 31, 2009.
Speaker, “How Do You Define ‘Design’ in a Design Defect Case,” IADC Mid-Year Meeting 2009, February 2009.
Invited panelist for Daily Journal-sponsored roundtable on product liability, published in the November 2008 issue of California Lawyer.
“Products Liability — Recall Related Evidence,” The National Law Journal, January 28, 2008.
“Take Your Medicine — Recalling a Defective Product Is a Company’s Best Option,” In-House Publication (a Dolan Media publication), January 2008.
Invited panelist for Daily Journal-sponsored roundtable on product liability, published in the December 2007 issue of California Lawyer.
Speaker for multi-venue MCLE presentation titled “Corporate Strategies That Win Jury Trials” for the Association of Corporate Counsel’s in-house counsel members, October 17, 2007.
ABA, Women In Products Liability Conference, Lunchtime Speaker: “There are Trials and You Can Win,” November 17, 2005.
Product Liability Update: “The End of An Era: Lessons to be Learned from the Bendectin Litigation” (1998).
In Re Rezulin Products Liability Litigation (2005) WL 583751 (S.D.N.Y.).
Daubert v. Merrell Dow Pharmaceuticals, Inc., 727 F.Supp. 570 (S.D. Cal. 1989); aff’d 951 F.2d 1128 (1991); 509 U.S. 579 (1993).
Obiago v. Merrell National Laboratory, Inc., 560 So. 2d 625 (La. App. 4 Cir); writ denied 565 So. 2d 445 (La. 1990).
Pamela was born and raised in England. She represented England in junior tennis matches and came to the US on a tennis scholarship. She is a three time NCAA Women’s Tennis Division II winner as well as a two time recipient of All American Honors. Additionally, Pamela was a recipient of the NCAA Postgraduate Scholarship in recognition of her academic and athletic achievements.